Lung Cancer:

1. Front Matter

   Pages i-xvi

   PDF

2. Molecular Pathology of Lung Cancer

   • Alejandro Corvalan, Ignacio I. Wistuba

   Pages 1-25

3. Tumor Microenvironment

   • Tonya C. Walser, Jane Yanagawa, Edward Garon, Jay M. Lee, Steven M. Dubinett

   Pages 27-69

4. Racial and Ethnic Diversity in Lung Cancer

   • Carol J. Etzel, Sumesh Kachroo

   Pages 71-85

5. Pharmacogenetics of Lung Cancer

   • Xifeng Wu, Jian Gu

   Pages 87-106

6. Lung Cancer Prevention

   • Nir Peled, Robert L. Keith, Fred R. Hirsch

   Pages 107-138

7. Adjuvant and Neoadjuvant Therapy of NSCLC

   • Katherine Pisters

   Pages 139-159

8. Chemoradiotherapy for Inoperable Non-small Cell Lung Cancer

   • James D. Cox, David J. Stewart

   Pages 161-175

9. Management of Advanced Non-small Cell Lung Cancer: Front Line Treatment

   • William N. William Jr., David J. Stewart

   Pages 177-194

10. Chemotherapy in Previously Treated Patients with Non-small Cell Lung Cancer

    • Frank V. Fossella

    Pages 195-204

11. Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer

    • Paul Wheatley-Price, Frances A. Shepherd

    Pages 205-226

12. Angiogenesis Inhibitors in Lung Cancer

    • Leora Horn, Alan Sandler

    Pages 227-252

13. Other Molecular Targeted Agents in Non-small Cell Lung Cancer

    • Benjamin Besse, Jean-Charles Soria

    Pages 253-278

14. Vaccine Therapy for Lung Cancer

    • John Nemunaitis, Jack Roth

    Pages 279-303

15. Gene-Based Therapies for Lung Cancer

    • John Nemunaitis, Jack Roth

    Pages 305-330

16. Lung Cancer Resistance to Chemotherapy

    • David J. Stewart

    Pages 331-393

17. Small Cell Carcinoma of the Lung

    • Emer O. Hanrahan, Bonnie Glisson

    Pages 395-434

18. Mesothelioma

    • Mary Frances McAleer, Reza J. Mehran, Anne Tsao

    Pages 435-465

19. Advances in Oncology Clinical Research: Statistical and Study Design Methodologies

    • B. Nebiyou Bekele

    Pages 467-481

20. Palliative Care for Patients with Lung Cancer

    • David Hui, Eduardo Bruera

    Pages 483-502

Defining the Lung Cancer Problem 1 Lung cancer is the leading cause of cancer death in the world. It kills almost as many Americans as cancers of the breast, prostate, colon, rectum, pancreas, and 2 kidney combined, and accounts for 28.6% of all US cancer deaths. With an increase in the 5-year relative survival rate from 13% to only 16% in the more than 2 30 years from 1974 to the present, it will take us another 840 years to eradicate lung cancer deaths if we do not improve the current rate of progress. As discussed in this text, lung cancer prevention has received substantial att- tion. The decrease in smoking in recent decades has helped, but smoking is not the only problem. Lung cancer in people who have never smoked is currently the 5th 3 leading cause of cancer death in the United States. Several factors contribute to the lethality of lung cancer, including the rapidity of tumor growth, advanced stage at diagnosis (due to nonspecificity of early sy- toms and the uncertain efficacy of screening), early development of metastases, and resistance to therapy. Several chapters in this book discuss new molecular targets that may be potentially exploitable in the future, as well as discussing our track record to date in exploiting them.

• Antiangiogenesis
• Cancer
• Carcinom
• Clinical trials
• Lung
• Malignancy
• Mesothelioma
• Non-small cell lung cancer (NSCLC)
• Novel Agents
• Prevention
• Small cell lung cancer (SCLC)
• Tho
• Thymoma
• cancer prevention
• Radiaton Oncology

From the reviews:

“This comprehensive review of prevention and treatment strategies for malignancies of the thorax thoroughly investigates tumor biology and discusses established and emerging therapies. … The book is written for a wide audience that includes pathologists, pulmonologists, medical oncologists, radiation oncologists, and surgical oncologists. … I would highly recommend this book to anyone interested in current and future therapies for lung cancer. This is one of the most comprehensive and up-to-date accounts of the field.” (Nagendra S. Koneru, Doody’s Review Service, July, 2010)

• M. D. Anderson Cancer Center, University of Texas, Houston, U.S.A.

  David J. Stewart

Policies and ethics